SEARCH

SEARCH BY CITATION

References

  • Ahmed, A.R., Spigelman, Z., Cavacini, L.A. & Posner, M.R. (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. The New England Journal of Medicine, 355, 17721779.
  • Albert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S., Tsai, D., Pullman-Mooar, S., Barnack, F., Striebich, C., Looney, R.J., Prak, E.T., Kimberly, R., Zhang, Y. & Eisenberg, R. (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Annals of the Rheumatic Diseases, 67, 17241731.
  • Almuti, K., Haythe, J., Dwyer, E., Itescu, S., Burke, E., Green, P., Marboe, C. & Mancini, D. (2007) The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation, 84, 498503.
  • Anolik, J.H., Campbell, D., Felgar, R.E., Young, F., Sanz, I., Rosenblatt, J. & Looney, R.J. (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis and Rheumatism, 48, 455459.
  • Aranda, Jr., J.M., Scornik, J.C., Normann, S.J., Lottenberg, R., Schofield, R.S., Pauly, D.F., Miles, M., Hill, J.A., Sleasman, J.W. & Skoda-Smith, S. (2002) Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation, 73, 907910.
  • Aries, P.M., Hellmich, B., Voswinkel, J., Both, M., Nolle, B., Holl-Ulrich, K., Lamprecht, P. & Gross, W.L. (2006) Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Annals of the Rheumatic Diseases, 65, 853858.
  • Bagnasco, S.M., Tsai, W., Rahman, M.H., Kraus, E.S., Barisoni, L., Vega, R., Racusen, L.C., Haas, M., Mohammed, B.S., Zachary, A.A. & Montgomery, R.A. (2007) CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival. American Journal of Transplantation, 7, 19681973.
  • Bar-Or, A., Calabresi, P.A., Arnold, D., Markowitz, C., Shafer, S., Kasper, L.H., Waubant, E., Gazda, S., Fox, R.J., Panzara, M., Sarkar, N., Agarwal, S. & Smith, C.H. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Annals of Neurology, 63, 395400.
  • Becker, Y.T., Becker, B.N., Pirsch, J.D. & Sollinger, H.W. (2004) Rituximab as treatment for refractory kidney transplant rejection. American Journal of Transplantation, 4, 9961001.
  • Benedetti, L., Briani, C., Franciotta, D., Carpo, M., Padua, L., Zara, G., Zambello, R., Sormani, M.P., Mancardi, G.L., Nobile-Orazio, E. & Schenone, A. (2008a) Long-term effect of rituximab in anti-mag polyneuropathy. Neurology, 71, 17421744.
  • Benedetti, L., Franciotta, D., Beronio, A., Cadenotti, L., Gobbi, M., Mancardi, G.L., Schenone, A. & Tartaglione, A. (2008b) Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle and Nerve, 38, 10761077.
  • Berinstein, N.L., Grillo-Lopez, A.J., White, C.A., Ce-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P. & Shen, D. (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Annals of Oncology, 9, 9951001.
  • Bierl, C., Miller, B., Prak, E.L., Gasiewski, A., Kearns, J., Tsai, D., Jessup, M. & Kamoun, M. (2006) Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal. Clinical Transplants, 2006, 489496.
  • Bonara, P., Vannucchi, G., Campi, I., Rossi, S., Cantoni, F., Frugoni, C., Sbrozzi, F., Guastella, C., Avignone, S., Beck-Peccoz, P. & Salvi, M. (2008) Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for graves’ ophthalmopathy. Clinical Reviews in Allergy & Immunology, 34, 118123.
  • Braun, A., Neumann, T., Oelzner, P., Hein, G., Grone, H.J., Ziemer, M. & Wolf, G. (2008) Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Rheumatology International, 28, 503506.
  • Cambridge, G., Stohl, W., Leandro, M.J., Migone, T.S., Hilbert, D.M. & Edwards, J.C. (2006a) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis and Rheumatism, 54, 723732.
  • Cambridge, G., Leandro, M.J., Teodorescu, M., Manson, J., Rahman, A., Isenberg, D.A. & Edwards, J.C. (2006b) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis and Rheumatism, 54, 36123622.
  • Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754758.
  • Chung, L., Genovese, M.C. & Fiorentino, D.F. (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Archives of Dermatology, 143, 763767.
  • Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., Keystone, E.C., Loveless, J.E., Burmester, G.R., Cravets, M.W., Hessey, E.W., Shaw, T. & Totoritis, M.C. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism, 54, 27932806.
  • Crawford, M.P., Yan, S.X., Ortega, S.B., Mehta, R.S., Hewitt, R.E., Price, D.A., Stastny, P., Douek, D.C., Koup, R.A., Racke, M.K. & Karandikar, N.J. (2004) High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood, 103, 42224231.
  • Crespo, M., Pascual, M., Tolkoff-Rubin, N., Mauiyyedi, S., Collins, A.B., Fitzpatrick, D., Farrell, M.L., Williams, W.W., Delmonico, F.L., Cosimi, A.B., Colvin, R.B. & Saidman, S.L. (2001) Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation, 71, 652658.
  • Cross, A.H., Stark, J.L., Lauber, J., Ramsbottom, M.J. & Lyons, J.A. (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. Journal of Neuroimmunology, 180, 6370.
  • Dass, S., Bowman, S.J., Vital, E.M., Ikeda, K., Pease, C.T., Hamburger, J., Richards, A., Rauz, S. & Emery, P. (2008) Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Annals of the Rheumatic Diseases, 67, 15411544.
  • Devauchelle-Pensec, V., Pennec, Y., Morvan, J., Pers, J.O., Daridon, C., Jousse-Joulin, S., Roudaut, A., Jamin, C., Renaudineau, Y., Roue, I.Q., Cochener, B., Youinou, P. & Saraux, A. (2007) Improvement of Sjogren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis and Rheumatism, 57, 310317.
  • Edwards, J.C. & Cambridge, G. (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford), 40, 205211.
  • Edwards, J.C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D.R., Stevens, R.M. & Shaw, T. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine, 350, 25722581.
  • Egawa, H., Ohmori, K., Haga, H., Tsuji, H., Yurugi, K., Miyagawa-Hayashino, A., Oike, F., Fukuda, A., Yoshizawa, J., Takada, Y., Tanaka, K., Maekawa, T., Ozawa, K. & Uemoto, S. (2007) B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transplantation, 13, 579588.
  • El Fassi, D., Nielsen, C.H., Hasselbalch, H.C. & Hegedus, L. (2006) Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid, 16, 709710.
  • El Fassi, D., Nielsen, C.H., Bonnema, S.J., Hasselbalch, H.C. & Hegedus, L. (2007) B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. The Journal of Clinical Endocrinology and Metabolism, 92, 17691772.
  • El Fassi, D., Banga, J.P., Gilbert, J.A., Padoa, C., Hegedus, L. & Nielsen, C.H. (2009) Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clinical Immunology, 130, 252258.
  • Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A.J., Van Vollenhoven, R.F., Li, N.F., Agarwal, S., Hessey, E.W. & Shaw, T.M. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis and Rheumatism, 54, 13901400.
  • Eming, R., Nagel, A., Wolff-Franke, S., Podstawa, E., Debus, D. & Hertl, M. (2008) Rituximab exerts a dual effect in pemphigus vulgaris. The Journal of Investigative Dermatology, 128, 28502858.
  • Fernandez-Fresnedo, G., Ramos, M.A., Gonzalez-Pardo, M.C., De Francisco, A.L., Lopez-Hoyos, M. & Arias, M. (2000) B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrology, Dialysis, Transplantation, 15, 502510.
  • Ferraro, A.J., Drayson, M.T., Savage, C.O. & MacLennan, I.C. (2008) Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. European Journal of Immunology, 38, 292298.
  • Fervenza, F.C., Cosio, F.G., Erickson, S.B., Specks, U., Herzenberg, A.M., Dillon, J.J., Leung, N., Cohen, I.M., Wochos, D.N., Bergstralh, E., Hladunewich, M. & Cattran, D.C. (2008) Rituximab treatment of idiopathic membranous nephropathy. Kidney International, 73, 117125.
  • Gajra, A., Vajpayee, N. & Grethlein, S.J. (2004) Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. American Journal of Hematology, 77, 196197.
  • Garrett, Jr., H.E., Duvall-Seaman, D., Helsley, B. & Groshart, K. (2005) Treatment of vascular rejection with rituximab in cardiac transplantation. The Journal of Heart and Lung Transplantation, 24, 13371342.
  • Genain, C.P., Cannella, B., Hauser, S.L. & Raine, C.S. (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Medicine, 5, 170175.
  • Genberg, H., Hansson, A., Wernerson, A., Wennberg, L. & Tyden, G. (2006) Pharmacodynamics of rituximab in kidney allotransplantation. American Journal of Transplantation, 6, 24182428.
  • Genberg, H., Kumlien, G., Wennberg, L., Berg, U. & Tyden, G. (2008) ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation, 85, 17451754.
  • Ginaldi, L., De, M.M., Matutes, E., Farahat, N., Morilla, R. & Catovsky, D. (1998) Levels of expression of CD19 and CD20 in chronic B cell leukaemias. Journal of Clinical Pathology, 51, 364369.
  • Glotz, D., Antoine, C., Julia, P., Suberbielle-Boissel, C., Boudjeltia, S., Fraoui, R., Hacen, C., Duboust, A. & Bariety, J. (2002) Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). American Journal of Transplantation, 2, 758760.
  • Gorson, K.C., Natarajan, N., Ropper, A.H. & Weinstein, R. (2007) Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle and Nerve, 35, 6669.
  • Gunnarsson, I., Sundelin, B., Jonsdottir, T., Jacobson, S.H., Henriksson, E.W. & Van Vollenhoven, R.F. (2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis and Rheumatism, 56, 12631272.
  • Hammond, E.H., Yowell, R.L., Nunoda, S., Menlove, R.L., Renlund, D.G., Bristow, M.R., Gay Jr., W.A., Jones, K.W. & O’Connell, J.B. (1989) Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. The Journal of Heart Transplantation, 8, 430443.
  • Harjunpaa, A., Junnikkala, S. & Meri, S. (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian Journal of Immunology, 51, 634641.
  • Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., Langer-Gould, A. & Smith, C.H. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. The New England Journal of Medicine, 358, 676688.
  • Hippen, B.E., DeMattos, A., Cook, W.J., Kew, C.E. & Gaston, R.S. (2005) Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. American Journal of Transplantation, 5, 22482252.
  • Illa, I., Az-Manera, J., Rojas-Garcia, R., Pradas, J., Rey, A., Blesa, R., Juarez, C. & Gallardo, E. (2008) Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. Journal of Neuroimmunology, 201202, 9094.
  • Ishida, H., Tanabe, K., Ishizuka, T., Furusawa, M., Miyamoto, N., Ishikawa, N., Shirakawa, H., Shimmura, H., Ishii, D., Nozaki, D., Setoguchi, K. & Toma, H. (2006) Differences in humoral immunity between a non-rejection group and a rejection group after ABO-incompatible renal transplantation. Transplantation, 81, 665671.
  • Jacob, A., Weinshenker, B.G., Violich, I., McLinskey, N., Krupp, L., Fox, R.J., Wingerchuk, D.M., Boggild, M., Constantinescu, C.S., Miller, A., De, A.T., Matiello, M. & Cree, B.A. (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Archives of Neurology, 65, 14431448.
  • Jillella, A.P., Dainer, P.M., Kallab, A.M. & Ustun, C. (2002) Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. American Journal of Hematology, 71, 219222.
  • Joly, P., Mouquet, H., Roujeau, J.C., D’Incan, M., Gilbert, D., Jacquot, S., Gougeon, M.L., Bedane, C., Muller, R., Dreno, B., Doutre, M.S., Delaporte, E., Pauwels, C., Franck, N., Caux, F., Picard, C., Tancrede-Bohin, E., Bernard, P., Tron, F., Hertl, M. & Musette, P. (2007) A single cycle of rituximab for the treatment of severe pemphigus. The New England Journal of Medicine, 357, 545552.
  • Jordan, S.C., Tyan, D., Stablein, D., McIntosh, M., Rose, S., Vo, A., Toyoda, M., Davis, C., Shapiro, R., Adey, D., Milliner, D., Graff, R., Steiner, R., Ciancio, G., Sahney, S. & Light, J. (2004) Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. Journal of the American Society of Nephrology, 15, 32563262.
  • Kaczmarek, I., Deutsch, M.A., Sadoni, S., Brenner, P., Schmauss, D., Daebritz, S.H., Weiss, M., Meiser, B.M. & Reichart, B. (2007) Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. The Journal of Heart and Lung Transplantation, 26, 511515.
  • Kaposztas, Z., Podder, H., Mauiyyedi, S., Illoh, O., Kerman, R., Reyes, M., Pollard, V. & Kahan, B.D. (2009) Impact of rituximab therapy for treatment of acute humoral rejection. (Abstract). Clinical Transplantation, 23, 6373.
  • Keogh, K.A., Wylam, M.E., Stone, J.H. & Specks, U. (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism, 52, 262268.
  • Keogh, K.A., Ytterberg, S.R., Fervenza, F.C., Carlson, K.A., Schroeder, D.R. & Specks, U. (2006) Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. American Journal of Respiratory and Critical Care Medicine, 173, 180187.
  • Kerjaschki, D. & Neale, T.J. (1996) Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). Journal of the American Society of Nephrology, 7, 25182526.
  • Keystone, E., Fleischmann, R., Emery, P., Furst, D.E., Van, V.R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., Udell, J., Cravets, M.W., Agarwal, S., Cooper, S. & Magrini, F. (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis and Rheumatism, 56, 38963908.
  • Kissel, J.T., Mendell, J.R. & Rammohan, K.W. (1986) Microvascular deposition of complement membrane attack complex in dermatomyositis. The New England Journal of Medicine, 314, 329334.
  • Koukoulaki, M., Abeygunasekara, S.C., Smith, K.G. & Jayne, D.R. (2005) Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrology, Dialysis, Transplantation, 20, 213216.
  • Lake-Bakaar, G., Dustin, L., McKeating, J., Newton, K., Freeman, V. & Frost, S.D. (2007) Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood, 109, 845846.
  • Leandro, M.J., Edwards, J.C. & Cambridge, G. (2002a) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Annals of the Rheumatic Diseases, 61, 883888.
  • Leandro, M.J., Edwards, J.C., Cambridge, G., Ehrenstein, M.R. & Isenberg, D.A. (2002b) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis and Rheumatism, 46, 26732677.
  • Leandro, M.J., Cambridge, G., Edwards, J.C., Ehrenstein, M.R. & Isenberg, D.A. (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford), 44, 15421545.
  • Leandro, M.J., Cambridge, G., Ehrenstein, M.R. & Edwards, J.C. (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis and Rheumatism, 54, 613620.
  • Levine, T.D. (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis and Rheumatism, 52, 601607.
  • Levine, T.D. & Pestronk, A. (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology, 52, 17011704.
  • Looney, R.J., Anolik, J.H., Campbell, D., Felgar, R.E., Young, F., Arend, L.J., Sloand, J.A., Rosenblatt, J. & Sanz, I. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis and Rheumatism, 50, 25802589.
  • Lovric, S., Erdbruegger, U., Kumpers, P., Woywodt, A., Koenecke, C., Wedemeyer, H., Haller, H. & Haubitz, M. (2009) Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrology, Dialysis, Transplantation, 24, 179185.
  • Lucchinetti, C.F., Mandler, R.N., McGavern, D., Bruck, W., Gleich, G., Ransohoff, R.M., Trebst, C., Weinshenker, B., Wingerchuk, D., Parisi, J.E. & Lassmann, H. (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain : A Journal of Neurology, 125, 14501461.
  • Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A. & Levy, R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 24572466.
  • Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. & Levy, R. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood, 90, 21882195.
  • Mauiyyedi, S. & Colvin, R.B. (2002) Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Current Opinion in Nephrology and Hypertension, 11, 609618.
  • McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Ce-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 28252833.
  • Meijer, J.M., Pijpe, J., Vissink, A., Kallenberg, C.G. & Bootsma, H. (2009) Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Annals of the Rheumatic Diseases, 68, 284285.
  • Merrill, J.T., Neuwelt, C.M., Wallace, D.J., Shanahan, J.C., Latinis, K.M., Oates, J.C., Utset, T.O., Gordon, C., Isenberg, D.A., Hsieh, H.J., Zhang, D. & Brunetta, P.G. (2008) Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomised, double-blind phase II/III study EXPLORER. (Abstract). Arthritis and Rheumatism, 58S, oral presentation L12.
  • Mok, C.C., Ho, L.Y. & To, C.H. (2007) Rituximab for refractory polymyositis: an open-label prospective study. The Journal of Rheumatology, 34, 18641868.
  • Molloy, E.S. & Calabrese, L.H. (2008) Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmunity Reviews, 8, 144146.
  • Montgomery, R.A., Zachary, A.A., Racusen, L.C., Leffell, M.S., King, K.E., Burdick, J., Maley, W.R. & Ratner, L.E. (2000) Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation, 70, 887895.
  • Mouquet, H., Musette, P., Gougeon, M.L., Jacquot, S., Lemercier, B., Lim, A., Gilbert, D., Dutot, I., Roujeau, J.C., D’Incan, M., Bedane, C., Tron, F. & Joly, P. (2008) B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. The Journal of Investigative Dermatology, 128, 28592869.
  • Mulley, W.R., Hudson, F.J., Tait, B.D., Skene, A.M., Dowling, J.P., Kerr, P.G. & Kanellis, J. (2009) A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation, 87, 286289.
  • Ng, K.P., Cambridge, G., Leandro, M.J., Edwards, J.C., Ehrenstein, M. & Isenberg, D.A. (2007) B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Annals of the Rheumatic Diseases, 66, 12591262.
  • Nived, O., Bengtsson, A.A., Jonsen, A. & Sturfelt, G. (2008) Progressive multifocal leukoencephalopathy – the importance of early diagnosis illustrated in four cases. Lupus, 17, 10361041.
  • Noss, E.H., Hausner-Sypek, D.L. & Weinblatt, M.E. (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. The Journal of Rheumatology, 33, 10211026.
  • Pestronk, A., Florence, J., Miller, T., Choksi, R., Al-Lozi, M.T. & Levine, T.D. (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 485489.
  • Petereit, H. & Rubbert-Roth, A. (2009) Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Multiple Sclerosis, 15, 189192.
  • Pijpe, J., Van Imhoff, G.W., Spijkervet, F.K., Roodenburg, J.L., Wolbink, G.J., Mansour, K., Vissink, A., Kallenberg, C.G. & Bootsma, H. (2005) Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis and Rheumatism, 52, 27402750.
  • Popa, C., Leandro, M.J., Cambridge, G. & Edwards, J.C. (2007) Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford), 46, 626630.
  • Press, O.W., Appelbaum, F., Ledbetter, J.A., Martin, P.J., Zarling, J., Kidd, P. & Thomas, E.D. (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood, 69, 584591.
  • Press, O.W., Howell-Clark, J., Anderson, S. & Bernstein, I. (1994) Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood, 83, 13901397.
  • Qin, Y., Duquette, P., Zhang, Y., Talbot, P., Poole, R. & Antel, J. (1998) Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. The Journal of Clinical Investigation, 102, 10451050.
  • Quartuccio, L., Soardo, G., Romano, G., Zaja, F., Scott, C.A., De, M.G., Fabris, M., Ferraccioli, G. & De, V.S. (2006) Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford), 45, 842846.
  • Quartuccio, L., Salvin, S., Fabris, M., Sacco, S. & De, V.S. (2008) Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy. Annals of the Rheumatic Diseases, 67, 14941495.
  • Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. & Anderson, D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435445.
  • Renaud, S., Gregor, M., Fuhr, P., Lorenz, D., Deuschl, G., Gratwohl, A. & Steck, A.J. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle and Nerve, 27, 611615.
  • Renaud, S., Fuhr, P., Gregor, M., Schweikert, K., Lorenz, D., Daniels, C., Deuschl, G., Gratwohl, A. & Steck, A.J. (2006) High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology, 66, 742744.
  • Reynolds, J., Toescu, V., Yee, C., Prabu, A., Situnayake, D. & Gordon, C. (2009) Effects of rituximab on resistant SLE disease including lung involvement. Lupus, 18, 6773.
  • Risselada, A.P. & Kallenberg, C.G. (2006) Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford), 45, 915916.
  • Roccatello, D., Baldovino, S., Rossi, D., Mansouri, M., Naretto, C., Gennaro, M., Cavallo, R., Alpa, M., Costanzo, P., Giachino, O., Mazzucco, G. & Sena, L.M. (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrology, Dialysis, Transplantation, 19, 30543061.
  • Roccatello, D., Baldovino, S., Alpa, M., Rossi, D., Napoli, F., Naretto, C., Cavallo, R. & Giachino, O. (2008) Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clinical and Experimental Dermatology, 26, S67S71.
  • Ruggenenti, P., Chiurchiu, C., Brusegan, V., Abbate, M., Perna, A., Filippi, C. & Remuzzi, G. (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. Journal of the American Society of Nephrology, 14, 18511857.
  • Rydberg, L. (2001) ABO-incompatibility in solid organ transplantation. Transfusion Medicine, 11, 325342.
  • Saadoun, D., Resche-Rigon, M., Sene, D., Perard, L., Karras, A. & Cacoub, P. (2008) Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Annals of the Rheumatic Diseases, 67, 14311436.
  • Saito, K., Nawata, M., Iwata, S., Tokunaga, M. & Tanaka, Y. (2005) Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. Rheumatology (Oxford), 44, 14621464.
  • Salant, D.J., Belok, S., Madaio, M.P. & Couser, W.G. (1980) A new role for complement in experimental membranous nephropathy in rats. The Journal of Clinical Investigation, 66, 13391350.
  • Salvi, M., Vannucchi, G., Campi, I., Curro, N., Dazzi, D., Simonetta, S., Bonara, P., Rossi, S., Sina, C., Guastella, C., Ratiglia, R. & Beck-Peccoz, P. (2007) Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology, 156, 3340.
  • Sansonno, D., De, R.V., Lauletta, G., Tucci, F.A., Boiocchi, M. & Dammacco, F. (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood, 101, 38183826.
  • Sarkar, K. & Miller, F.W. (2004) Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies. Autoimmunity, 37, 291294.
  • Scheepstra, C., Bemelman, F.J., Van Der Loos, C., Rowshani, A.T., Van Donselaar-Van der Pant, K.A., Idu, M.M., Ten, B.I. & Florquin, S. (2008) B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection. Transplantation, 86, 772778.
  • Seror, R., Sordet, C., Guillevin, L., Hachulla, E., Masson, C., Ittah, M., Candon, S., Le, G.V., Aouba, A., Sibilia, J., Gottenberg, J.E. & Mariette, X. (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome. Annals of the Rheumatic Diseases, 66, 351357.
  • Sfikakis, P.P., Boletis, J.N., Lionaki, S., Vigklis, V., Fragiadaki, K.G., Iniotaki, A. & Moutsopoulos, H.M. (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis and Rheumatism, 52, 501513.
  • Sfikakis, P.P., Souliotis, V.L., Fragiadaki, K.G., Moutsopoulos, H.M., Boletis, J.N. & Theofilopoulos, A.N. (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clinical Immunology, 123, 6673.
  • Shams’ili, S., De, B.J., Gratama, J.W., Hooijkaas, H., Van Den Bent M., Van., ’t Veer, M. & Sillevis, S.P. (2006) An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Journal of Neurology, 253, 1620.
  • Shan, D., Ledbetter, J.A. & Press, O.W. (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood, 91, 16441652.
  • Siden, A. (1979) Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS. Journal of Neurology, 221, 3951.
  • Smith, K.G., Jones, R.B., Burns, S.M. & Jayne, D.R. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis and Rheumatism, 54, 29702982.
  • Sonnenday, C.J., Warren, D.S., Cooper, M., Samaniego, M., Haas, M., King, K.E., Shirey, R.S., Simpkins, C.E. & Montgomery, R.A. (2004) Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. American Journal of Transplantation, 4, 13151322.
  • Squifflet, J.P., De Meyer, M., Malaise, J., Latinne, D., Pirson, Y. & Alexandre, G.P. (2004) Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Experimental and Clinical Transplantation, 2, 208213.
  • Steinmetz, O.M., Lange-Husken, F., Turner, J.E., Vernauer, A., Helmchen, U., Stahl, R.A., Thaiss, F. & Panzer, U. (2007) Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation, 84, 842850.
  • Tak, P.P., Cohen, S., Emery, P., Saadeh, C.K., De Vita, S., Donohue, J.P., McDabe, D.P., Shaw, T. & Magrini, F. (2006) Baseline autoantibody status (RF, anti-CCP) and clinical response following the first treatment course with rituximab. (Abstract). Arthritis and Rheumatism, 54(Suppl), Presentation 833.
  • Tanabe, K., Ishida, H., Shimizu, T., Omoto, K., Shirakawa, H. & Tokumoto, T. (2009) Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contributions to Nephrology, 162, 6174.
  • Todd, D.J. & Helfgott, S.M. (2007) Serum sickness following treatment with rituximab. The Journal of Rheumatology, 34, 430433.
  • Tokunaga, M., Fujii, K., Saito, K., Nakayamada, S., Tsujimura, S., Nawata, M. & Tanaka, Y. (2005) Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford), 44, 176182.
  • Tokunaga, M., Saito, K., Kawabata, D., Imura, Y., Fujii, T., Nakayamada, S., Tsujimura, S., Nawata, M., Iwata, S., Azuma, T., Mimori, T. & Tanaka, Y. (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Annals of the Rheumatic Diseases, 66, 470475.
  • Touma, Z., Arayssi, T., Kibbi, L. & Masri, A.F. (2008) Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint, Bone, Spine, 75, 334337.
  • Tyden, G., Donauer, J., Wadstrom, J., Kumlien, G., Wilpert, J., Nilsson, T., Genberg, H., Pisarski, P. & Tufveson, G. (2007) Implementation of a protocol for ABO-incompatible kidney transplantation – a three-center experience with 60 consecutive transplantations. Transplantation, 83, 11531155.
  • Usuda, M., Fujimori, K., Koyamada, N., Fukumori, T., Sekiguchi, S., Kawagishi, N., Akamatsu, Y., Enomoto, Y., Satoh, K., Satoh, A., Ishida, K., Moriya, T. & Satomi, S. (2005) Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation, 79, 1216.
  • Usui, M., Isaji, S., Mizuno, S., Sakurai, H. & Uemoto, S. (2007) Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation. Clinical Transplantation, 21, 2431.
  • Vallerskog, T., Gunnarsson, I., Widhe, M., Risselada, A., Klareskog, L., Van Vollenhoven, R., Malmstrom, V. & Trollmo, C. (2007) Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clinical Immunology, 122, 6274.
  • Vieira, C.A., Agarwal, A., Book, B.K., Sidner, R.A., Bearden, C.M., Gebel, H.M., Roggero, A.L., Fineberg, N.S., Taber, T., Kraus, M.A. & Pescovitz, M.D. (2004) Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation, 77, 542548.
  • Viglietta, V., Baecher-Allan, C., Weiner, H.L. & Hafler, D.A. (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. The Journal of Experimental Medicine, 199, 971979.
  • Vigna-Perez, M., Hernandez-Castro, B., Paredes-Saharopulos, O., Portales-Perez, D., Baranda, L., Bud-Mendoza, C. & Gonzalez-Amaro, R. (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Research & Therapy, 8, R83.
  • Visentini, M., Granata, M., Veneziano, M.L., Borghese, F., Carlesimo, M., Pimpinelli, F., Fiorilli, M. & Casato, M. (2007) Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clinical Immunology, 125, 3033.
  • Vo, A.A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N.L., Lai, C.H., Peng, A., Villicana, R. & Jordan, S.C. (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. The New England Journal of Medicine, 359, 242251.
  • Watson, R., Kozlowski, T., Nickeleit, V., Woosley, J.T., Schmitz, J.L., Zacks, S.L., Fair, J.H., Gerber, D.A. & Andreoni, K.A. (2006) Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. American Journal of Transplantation, 6, 30223029.
  • Weide, R., Heymanns, J., Pandorf, A. & Koppler, H. (2003) Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus, 12, 779782.
  • Zaja, F., De, V.S., Mazzaro, C., Sacco, S., Damiani, D., De, M.G., Michelutti, A., Baccarani, M., Fanin, R. & Ferraccioli, G. (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood, 101, 38273834.
  • Zapata, L.F., Agudelo, L.M., Paulo, J.D. & Pineda, R. (2007) Sjogren keratoconjunctivitis sicca treated with rituximab. Cornea, 26, 886887.